<unk>  has been produced by Bristol Myers Squibb but it is marketed as an orphan drug for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. In a 2007 retrospective study of 177 patients from 1985 to 2005 showed a significant increase in the recurrence-free interval after radical surgery followed by<unk>  when compared to surgery alone. The drug is also sometimes used in the treatment of Cushing's syndrome.
Mitotane
Tamoxifen
Exemestane
Fluoxymesterone
Aminoglutethimide
Formestane
Salvestrol
Ethisterone